Hester Biosciences Peer Comparison

NSE: HESTERBIO | BSE: 524669

₹2,308.90

₹-56.50 (-2.39%)

As on 09-Nov-2026IST

Market cap

₹1,949 Cr

Revenue (TTM)

₹353 Cr

P/E Ratio

13.7

P/B Ratio

4.2

Div. Yield

0.5 %

Edit

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Market cap (₹ Cr)	1,949	1,811	42,042	32,864	33,015
Revenue (₹ Cr)	353	575	10,234	9,779	3,751
Net Profit (₹ Cr)	136.11	63.82	1,092.67	-270.51	405.00
Net Margin (%)	38.50	10.81	10.67	-2.71	10.48
RoE (%)	13.69	18.45	21.65	-2.55	7.91
Price to Earnings	13.72	28.38	38.45	--	80.52
Price-To-Book	4.17	5.00	7.87	4.03	6.40

Income Statement (₹ Cr)

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Operating Revenue	352.68	574.61	10,234.10	9,778.62	3,751.00
Total Income	353.50	590.31	10,245.27	9,993.26	3,863.00
Total Expenditure	245.12	479.53	8,141.47	8,578.44	2,984.00
EBITDA	107.56	95.08	2,092.63	1,200.18	767.00
Depreciation	24.47	22.04	430.12	887.82	228.00
EBIT	83.10	73.04	1,662.51	312.36	539.00
Interest	12.98	4.19	151.49	347.94	218.00
Other Income	0.82	15.70	11.17	214.64	112.00
Exceptional Items	88.70	0.00	-27.85	-216.88	12.00
Profit before Tax	159.64	84.56	1,494.35	-37.82	445.00
Provision for Tax	23.53	20.74	401.68	232.69	40.00
Profit after Tax	136.11	63.82	1,092.67	-270.51	405.00

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Shareholder's Funds	467.78	362.61	5,344.04	8,142.24	5,158.00
Minority Interest	-1.13	0.00	0.82	0.55	5.00
Non-Current Liabilities	109.01	67.51	980.81	5,213.99	1,617.00
Current Liabilities	98.90	197.64	3,838.93	5,158.51	1,785.00
Total Liabilities	677.94	560.46	9,514.48	17,723.32	8,578.00

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Non-Current Assets	453.07	286.29	3,542.74	10,687.30	5,527.00
Current Assets	221.80	323.26	6,027.59	7,253.65	2,764.00
Total Assets	677.94	560.46	9,514.48	17,723.32	8,578.00
Total Debt*	188.26	122.50	1,204.08	5,495.48	2,125.00
Net Current Assets	122.90	125.62	2,188.66	2,095.14	979.00
Contingent Liabilities	--	0.80	258.92	95.72	768.26

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Cash From Operating Activities	64.14	43.32	943.55	1,652.60	390.00
Cash Flow from Investing Activities	-2.87	-70.59	-1,193.06	-826.03	-241.00
Cash from Financing Activities	-48.79	29.55	343.43	-38.98	-54.00
Net Cash Inflow / Outflow	12.48	2.27	93.92	787.59	95.00

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
ROCE (%)	16.21	16.88	25.25	1.24	6.79
ROE (%)	13.69	18.45	21.65	-2.55	7.91
ROA (%)	20.04	11.48	11.17	-1.56	4.65
EBIT Margin (%)	23.56	12.71	16.24	3.19	14.37
Net Margin (%)	38.50	10.81	10.67	-2.71	10.48
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Revenue Growth (%)	17.48	40.66	21.12	9.43	25.70
EBIT Growth (%)	98.93	207.19	32.84	-3.72	139.56
Net Profit Growth (%)	248.19	208.49	33.33	-199.34	894.12
EPS Growth (%)	29.22	208.49	38.63	-410.28	599.72
Book Value Growth (%)	14.63	16.57	11.36	0.33	13.47

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Price / Earnings	34.40	28.38	37.72	-158.04	82.63
Price / Book Value	4.17	5.00	7.87	4.03	6.40
Dividend Yield (%)	0.48	0.06	0.16	0.00	0.00
EV/EBITDA	19.81	19.87	20.60	30.83	44.95
Market Cap (₹ Cr)	1,074.13	1,279.54	30,257.56	18,108.89	19,071.62

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Debt to Equity	0.09	0.14	0.10	0.55	0.28
Short term debt to equity ratio	0.07	0.16	0.16	0.09	0.09
Current Ratio	2.24	1.64	1.57	1.41	1.55
Quick Ratio	1.45	1.04	0.92	0.77	1.00
Interest Coverage	13.30	21.20	10.86	0.89	3.04

	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Debtors to sales (%)	23.16	23.80	26.69	23.05	16.85
Asset Turnover	0.52	1.03	1.05	0.56	0.43
Receivable days	92.43	77.86	88.68	78.20	58.75
Inventory Days	78.37	44.28	84.11	93.30	75.82
Payable days	120.46	88.92	176.65	226.14	186.21
Cash Conversion Cycle	50.33	33.22	-3.86	-54.64	-51.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.